The American Hospital Association is urging federal regulators to intervene against Eli Lilly and Novo Nordisk, which have imposed expanded data reporting requirements on providers participating in the 340B drug discount program.

The 340B program allows eligible hospitals and clinics to purchase outpatient drugs at significant discounts—often 25-50% below wholesale. Drug manufacturers have increasingly pushed back, arguing the program has expanded beyond its original intent. Lilly and Novo Nordisk are now requiring providers to submit detailed claims data on 340B-dispensed drugs, a demand the AHA calls onerous and unlawful. The hospitals' argument: HRSA (the federal agency overseeing 340B) has not authorized these data requirements, and manufacturers are unilaterally imposing conditions that threaten the financial viability of safety-net providers.

For health systems that rely on 340B savings to fund charity care, community health programs, and operational margins, this is an existential fight. The spread between 340B acquisition costs and reimbursement rates represents billions of dollars annually across the healthcare system. If manufacturers successfully restrict the program through data compliance barriers, hospitals will lose a critical revenue stream that subsidizes care for underserved populations.

What to watch: HRSA's response to the AHA petition, whether additional manufacturers adopt similar data requirements, and potential legislative action to codify 340B protections.